Institutional members access full text with Ovid®

Share this article on:

Comparison of Clinical Efficacies of Autologous Serum Eye Drops in Patients With Primary and Secondary Sjögren Syndrome

Hwang, Jehyung MD; Chung, So-Hyang MD, PhD; Jeon, Sohee MD; Kwok, Seung-Ki MD, PhD; Park, Sung-Hwan MD, PhD; Kim, Man-Soo MD, PhD

doi: 10.1097/ICO.0000000000000147
Clinical Science

Purpose: Autologous serum eye drops are considered to be safe and efficient for the treatment of dry eyes associated with Sjögren syndrome (SS). The purpose of this study was to compare the clinical efficacies of autologous serum eye drops in the management of primary and secondary SS.

Methods: Patients with primary (n = 20; 35 eyes) and secondary (n = 14; 27 eyes) SS dry eye were included. Serum concentrations of proinflammatory cytokines [tumor necrosis factor α, interleukin (IL)-1β, IL-6, and IL-8] were measured by a multiplex immunobead assay. The ocular symptom scores, ocular staining grades, and tear break-up time were evaluated before and after 4 weeks of 50% autologous serum eye drop application.

Results: At enrollment, patients with secondary SS had higher serum proinflammatory cytokine levels (tumor necrosis factor α, IL-1β, IL-6, and IL-8) than patients with primary SS (P < 0.01). After 4 weeks of autologous serum eye drop treatment, patients with primary SS had significantly improved ocular symptoms (P < 0.01), ocular surface staining grades (P < 0.01), and tear break-up time (P < 0.05). However, patients with secondary SS had no improvement (P > 0.05).

Conclusions: Our results suggest that autologous serum eye drops might not be effective for the treatment of secondary SS because of elevated serum proinflammatory cytokine levels.

*Department of Ophthalmology, Sanggye Paik Hospital, Seoul, Korea;

Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea;

Catholic Institute of Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea;

§Department of Medical Life Science, The Catholic University of Korea, Seoul, Korea;

Catholic High Performance Cell Therapy Center, The Catholic University of Korea, Seoul, Korea; and

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Reprints: So-Hyang Chung, Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #505 Banpo-Dong, Seocho-Gu, Seoul, 137-040, Korea (e-mail: chungsh@catholic.ac.kr).

The authors have no conflicts of interest to disclose.

Supported by a grant of the Korea Health Technology R&D Project, Ministry of Health & Welfare, Korea (HI13C0016).

Received December 23, 2013

Accepted April 02, 2014

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.